Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes
NCT ID: NCT03204799
Last Updated: 2019-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2016-12-17
2019-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, the investigators investigate the composite of microbiota and deduct basic information for treatment models using metagenomic sequencing.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gut Microbiota and Bile Acids in Type 2 Diabetes Mellitus
NCT04194515
Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk
NCT04579900
Fecal Microbiota Transplantation on Type 2 Diabetes Mellitus
NCT01790711
The Alteration of Gut Microbiota and Analysis of Related Factors in Newly Diagnosed Type 2 Diabetes Patients
NCT05752851
Altered Faecal Microbiome and Metabolome in CT1D, AT1D and T2D
NCT05252728
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Observational prospective study: metformin/sodium glucose co-transporter 2 (SGLT2) inhibitor/ezetimibe: compare microbiota using metagenomic sequencing before and after drug treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
normal group
normal group (without diabetes diagnosis/treatment and in normoglycemia
Metformin
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
ezetimibe
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
prediabetes
high risk, impaired fasting glucose, impaired glucose tolerance
Metformin
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
ezetimibe
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
drug naive type 2 diabetes
type 2 diabetes, anti-hypoglycemic drug naive
Metformin
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
ezetimibe
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
type 2 diabetes with metformin monotherapy
type 2 diabetes with metformin monotherapy
Metformin
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
type 2 diabetes with SGLT2 inhibitor monotherapy
type 2 diabetes with SGLT2 inhibitor monotherapy
SGLT2 inhibitor
newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
dyslipidemia with ezetimibe therapy
dyslipidemia with ezetimibe therapy
ezetimibe
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
SGLT2 inhibitor
newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
ezetimibe
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* prediabetes group: fasting blood glucose ≥100 mg/dL and \<126 mg/dL or postprandial blood glucose ≥140 mg/dL and \<200 mg/dL
* type 2 diabetes according to ADA(American Diabetes Association) guideline (1) fasting blood glucose ≥126 mg/dL, (2) random blood glucose ≥200 mg/dL and with typical diabetes symptoms, (3) glycated hemoglobin A1c ≥6.5% and anti-hypoglycemic drug naive
* patients with type 2 diabetes, metformin monotherapy, SGLT2 inhibitor monotherapy
* patients with dyslipidemia, ezetimibe therapy
Exclusion Criteria
* history of stomach, small intestine or colon resection operation
* on antibiotics therapy
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4-2016-0950
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.